AntiPD1
PreclinicalSmall molecule
AntiPD1 is one of 55 small molecule programs targeting Cutaneous Melanoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Cutaneous Melanoma
#DrugCompanyPhaseTrials
1Tafinlar
NovartisPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
DTIC-Dome
BayerPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Intron a
Merck & Co.Phase 3
PEG-Intron
Merck & Co.Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AntiPD1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAzienda Ospedaliera di Perugia